EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Emzahh (Norethindrone Tablets USP), 0.35mg. Aurobindo Pharma’s Emzahh (Norethindrone Tablets USP), are an AB-rated generic equivalent to the reference listed drug (RLD), ORTHO MICRONOR Tablets manufactured by Janssen Pharmaceuticals Inc.

Emzahh (Norethindrone Tablets USP), are indicated for the prevention of pregnancy.

Emzahh (Norethindrone Tablets USP) has an estimated market size of US $101 million for the twelve months ending November 2022, as per IQVIA.